- Home
- PRT vs JSPR Comparison
PRT vs JSPR Comparison
Compare PRT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | JSPR |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 26.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRT | JSPR |
|---|---|---|
| Price | $2.09 | $0.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 25.1K | ★ 424.1K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 13.45% | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $0.32 |
| 52 Week High | $4.01 | $2.69 |
Technical Indicators
Market Signals| Indicator | PRT | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 33.40 | 33.49 |
| Support Level | $2.02 | $0.55 |
| Resistance Level | $2.32 | $0.60 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 17.86 | 1.25 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.